Detection of PIK3CA mutations in circulating free DNA in patients with breast cancer

Breast Cancer Research and Treatment

Volumn 120, Issue 2, 2010, Pages 461-467

  Board, Ruth E ^a,b   Wardley, Andrew M ^b   Dixon, J Michael ^c,d   Armstrong, Anne C ^b   Howell, Sacha ^b   Renshaw, Lorna ^c,d   Donald, Emma ^e   Greystoke, Alastair ^a,b   Ranson, Malcolm ^a,b   Hughes, Andrew ^e   Dive, Caroline ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b CHRISTIE HOSPITAL   (United Kingdom)

^c WESTERN GENERAL HOSPITAL   (United Kingdom)

^d Breakthrough Research Unit   (United Kingdom)

^e ASTRAZENECA   (United Kingdom)

Author keywords

Breast cancer; Circulating free DNA; PIK3CA mutations; Predictive biomarker

Indexed keywords

BIOLOGICAL MARKER; DNA; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOINOSITIDE 3 KINASE CATALYTIC ALPHA POLYPEPTIDE; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLOOD SAMPLING; BREAST CANCER; BREAST CARCINOGENESIS; CANCER GRADING; CANCER LOCALIZATION; CLINICAL ARTICLE; CONTROLLED STUDY; DNA EXTRACTION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; METASTASIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SOMATIC MUTATION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ADULT; AGED; BREAST NEOPLASMS; DNA; DNA MUTATIONAL ANALYSIS; FEMALE; HUMANS; MIDDLE AGED; MUTATION;

EID: 77950689916     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-010-0747-9     Document Type: Article

References (25)

1. 1. Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, Yan H, Gazdar A, Powell SM, Riggins GJ, Willson JK, Markowitz S, Kinzler KW, Vogelstein B, Velculescu VE (2004) High frequency of mutations of the PIK3CA gene in human cancers. Science 304(5670):554 (Pubitemid 38541907)
2. 2. Kang S, Bader AG, Vogt PK (2005) Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic. Proc Natl Acad Sci USA 102(3):802-807 (Pubitemid 40282746)
3. 3. Gymnopoulos M, Elsliger MA, Vogt PK (2007) Rare cancerspecific mutations in PIK3CA show gain of function. Proc Natl Acad Sci USA 104(13):5569-5574 (Pubitemid 47175721)
4. 4. Samuels Y, Diaz LA Jr, Schmidt-Kittler O, Cummins JM, Delong L, Cheong I, Rago C, Huso DL, Lengauer C, Kinzler KW, Vogelstein B, Velculescu VE (2005) Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell 7(6):561-573 (Pubitemid 40799249)
5. 5. IhIe NT, Williams R, Chow S, Chew W, Berggren MI, PaineMurrieta G, Minion DJ, Halter RJ, Wipf P, Abraham R, Kirkpatrick L, Powis G (2004) Molecular pharmacology and antitumor activity of PX-866, a novel inhibitor of phosphoinositide-3kinase signaling. MoI Cancer Ther 3(7):763-772 (Pubitemid 39193758)
6. Serra V, Markman B, Scaltriti M, Eichhorn PJ, Valero V, Guzman M, Botero ML, Llonch E, Atzori F, Di Cosimo S, Maira M, Garcia-Echeverria C, Parra JL, Arribas J, Baselga J (2008) NVPBEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. Cancer Res 68(19):8022-8030
7. Eichhorn PJ, Gili M, Scaltriti M, Serra V, Guzman M, Nijkamp W, Beijersbergen RL, Valero V, Seoane J, Bernards R, Baselga J (2008) Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235. Cancer Res 68(22): 9221-9230
8. 8. Saal LH, Holm K, Maurer M, Memeo L, Su T, Wang X, Yu JS, Malmstrom PO, Mansukhani M, Enoksson J, Hibshoosh H, Borg A, Parsons R (2005) PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res 65(7):2554-2559 (Pubitemid 40490050)
9. 9. Campbell IG, Russell SE, Choong DY, Montgomery KG, Ciavarella ML, Hooi CS, Cristiano BE, Pearson RB, Phillips WA (2004) Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res 64(21):7678-7681 (Pubitemid 39446895)
10. 10. Levine DA, Bogomolniy F, Yee CJ, Lash A, Barakat RR, Borgen PI, Boyd J (2005) Frequent mutation of the PIK3CA gene in ovarian and breast cancers. Clin. Cancer Res 11(8):2875-2878 (Pubitemid 40525186)
11. 11. Bachman KE, Argani P, Samuels Y, Silliman N, Ptak J, Szabo S, Konishi H, Karakas B, Blair BG, Lin C, Peters BA, Velculescu VE, Park BH (2004) The PIK3C A gene is mutated with high frequency in human breast cancers. Cancer Biol Ther 3(8):772-775 (Pubitemid 41351083)
12. Lee JW, Soung YH, Kim SY, Lee HW, Park WS, Nam SW, Kim SH, Lee JY, Yoo NJ, Lee SH (2005) PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas. Oncogene 24(8): 1477-1480
13. 13. Berns K, Horlings HM, Hennessy BT, Madiredjo M, Hijmans EM, Beelen K, Linn SC, Gonzalez-Angulo AM, Stemke-Hale K, Hauptmann M, Beijersbergen RL, Mills GB, van de Vijver MJ, Bernards R (2007) A functional genetic approach identifies the PI3 K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 12(4):395-402 (Pubitemid 47539306)
14. 14. Leon SA, Shapiro B, Sklaroff DM, Yaros MJ (1977) Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res 37(3):646-650 (Pubitemid 8051621)
15. 15. Kimura H, Kasahara K, Kawaishi M, Kunitoh H, Tamura T, Holloway B, Nishio K (2006) Detection of epidermal growth factor receptor mutations in serum as a predictor of the response to gefitinib in patients with non-small-cell lung cancer. Clin Cancer Res 12(1.3):3915-3921 (Pubitemid 44078075)
16. 16. Kimura H, Suminoe M, Kasahara K, Sone T, Araya T, Tamori S, Koizumi F, Nishio K, Miyamoto K, Fujimura M, Nakao S (2007) Evaluation of epidermal growth factor receptor mutation status in serum DNA as a predictor of response to gefitinib (IRESSA), Br J Cancer 97(6):778-784 (Pubitemid 47396294)
17. 17. Sorenson GD (2000) Detection of mutated KRAS2 sequences as tumor markers in plasma/serum of patients with gastrointestinal cancer. Clin Cancer Res 6(6):2129-2137 (Pubitemid 30399177)
18. 18. Yancovitz M, Yoon J, Mikhail M, Gai W, Shapiro RL, Berman RS, Pavlick AC, Chapman PB, Osman I, Polsky D (2007) Detection of mutant BRAF alleles in the plasma of patients with metastatic melanoma. J Mol Diagn 9(2):178-183 (Pubitemid 47305084)
19. 19. Daniotti M, Vallacchi V, Rivoltini L, Patuzzo R, Santinami M, Arienti F, Cutolo G, Pierotti MA, Parmiani G, Rodolfo M (2007) Detection of mutated BRAFV600E variant in circulating DNA of stage III-IV melanoma patients. Int J Cancer 120(11):2439-2444 (Pubitemid 46642132)
20. 20. Board RE, Thelwell NJ, Ravetto PF, Little S, Ranson M, Dive C, Hughes A, Whitcombe D (2008) Multiplexed assays for detection of mutations in PIK3CA. Clin Chem 54(4):757-760 (Pubitemid 351573719)
21. Coombs NJ, Gough AC, Primrose JN (1999) Optimisation of DNA and RNA extraction from archival formalin-fixed tissue, Nucleic Acids Res 27(16):e12
22. Diehl F, Li M, Dressman D, He Y, Shen D, Szabo S, Diaz LA Jr, Goodman SN, David KA, Juhl H, Kinzler KW, Vogelstein B (2005) Detection and quantification, of mutations in the plasma of patients with colorectal tumors Proc Natl Acad Sci USA 102(45):16368-16373
23. 23. Wang JY, Hsieh JS, Chang MY, Huang TJ, Chen FM, Cheng TL, Alexandersen K, Huang YS, Tzou WS, Lin SR (2004) Molecular detection, of APC, K-ras, and p53 mutations in the serum, of colorectal cancer patients as circulating biomarkers. World J Surg 28(7)721-726 (Pubitemid 39097133)
24. Hayes DF, Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Miller MC, Matera J, Allard WJ, Doyle GV, Terstappen LW (2006) Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progressionfree and overall survival. Clin Cancer Res 12(14 Pt 1):4218-4224
25. 25. Ramirez JL, Sarries C, de Castro PL, Roig B, Queralt C, Escuin D, de Aguirre I, Sanchez JM, Manzano JL, Margeli M, Sanchez JJ, Astudillo J, Taron M, Roseli R (2003) Methylation patterns and K-ras mutations in tumor and paired serum of resected nonsmall-cell lung cancer patients. Cancer Lett 193(2):207-216 (Pubitemid 36428904)